VYNE Therapeutics Announces Phase Ib Data for FMX114 from Phase Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

By
Justin.choi
-
0
34
VYNE Therapeutics, Inc. announced that it has completed the Phase Ib portion of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis
[VYNE Therapeutics, Inc.]

Sorry, but the selected Zotpress account can't be found.

Press Release